These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 10618007)
41. Cholinergic markers in the cortex and hippocampus of some animal species and their correlation to Alzheimer's disease. Orta-Salazar E; Cuellar-Lemus CA; Díaz-Cintra S; Feria-Velasco AI Neurologia; 2014 Oct; 29(8):497-503. PubMed ID: 23433740 [TBL] [Abstract][Full Text] [Related]
43. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Cummings JL; Back C Am J Geriatr Psychiatry; 1998; 6(2 Suppl 1):S64-78. PubMed ID: 9581223 [TBL] [Abstract][Full Text] [Related]
47. The role of cholinergic balance perturbation in neurological diseases. Nizri E; Wirguin I; Brenner T Drug News Perspect; 2007 Sep; 20(7):421-9. PubMed ID: 17992264 [TBL] [Abstract][Full Text] [Related]
48. [Tacrine]. Dávila C; Viteri C; de Castro P Rev Med Univ Navarra; 1997; 41(1):58-64. PubMed ID: 9527715 [TBL] [Abstract][Full Text] [Related]
49. Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice. Frisoni GB J Neurol; 2001 Jul; 248(7):551-7. PubMed ID: 11517995 [TBL] [Abstract][Full Text] [Related]
50. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease. Relkin NR Expert Rev Neurother; 2007 Jun; 7(6):735-48. PubMed ID: 17561789 [TBL] [Abstract][Full Text] [Related]
51. Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease. Cummings J; Zhong K Clin Pharmacol Ther; 2015 Nov; 98(5):483-5. PubMed ID: 26206713 [TBL] [Abstract][Full Text] [Related]
52. A Current Perspective on the Inhibition of Cholinesterase by Natural and Synthetic Inhibitors. Shah AA; Dar TA; Dar PA; Ganie SA; Kamal MA Curr Drug Metab; 2017; 18(2):96-111. PubMed ID: 27890007 [TBL] [Abstract][Full Text] [Related]
53. Treating disorders across the lifespan by modulating cholinergic signaling with galantamine. Metz CN; Pavlov VA J Neurochem; 2021 Sep; 158(6):1359-1380. PubMed ID: 33219523 [TBL] [Abstract][Full Text] [Related]
54. Neuropsychiatric symptoms of dementia: are pharmacological treatments effective and safe? Ford AH J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):4. PubMed ID: 24876187 [No Abstract] [Full Text] [Related]
55. [Treating cognitive disorders in Alzheimer's disease: yes, but not only that]. Forette F Presse Med; 2003 Jul; 32(24 Suppl):S3-4. PubMed ID: 12947600 [No Abstract] [Full Text] [Related]
56. Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Camps P; Muñoz-Torrero D Mini Rev Med Chem; 2002 Feb; 2(1):11-25. PubMed ID: 12369954 [TBL] [Abstract][Full Text] [Related]
57. Biochemical pathology and treatment strategies in Alzheimer's disease: emphasis on the cholinergic system. Winblad B; Messamore E; O'Neill C; Cowburn R Acta Neurol Scand Suppl; 1993; 149():4-6. PubMed ID: 8128837 [TBL] [Abstract][Full Text] [Related]
58. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. Lawrence AD; Sahakian BJ Neurochem Res; 1998 May; 23(5):787-94. PubMed ID: 9566619 [TBL] [Abstract][Full Text] [Related]
59. Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases. Van der Schyf CJ Drug Dev Res; 2016 Dec; 77(8):458-468. PubMed ID: 27813127 [TBL] [Abstract][Full Text] [Related]
60. A second wind for the cholinergic system in Alzheimer's therapy. Douchamps V; Mathis C Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):112-123. PubMed ID: 28240674 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]